These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22441310)

  • 21. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2010 Jun; 105(11):1541-7. PubMed ID: 19912191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer.
    Bolton DM; Ta A; Bagnato M; Muller D; Lawrentschuk NL; Severi G; Syme RR; Giles GG
    World J Urol; 2014 Apr; 32(2):431-5. PubMed ID: 23824175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer.
    Kang HW; Jung HD; Lee JY; Kwon JK; Jeh SU; Cho KS; Ham WS; Choi YD
    Asian J Androl; 2016; 18(3):480-4. PubMed ID: 26178393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.
    Ho T; Gerber L; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):910-6. PubMed ID: 22921964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Van den Broeck T; van den Bergh RCN; Arfi N; Gross T; Moris L; Briers E; Cumberbatch M; De Santis M; Tilki D; Fanti S; Fossati N; Gillessen S; Grummet JP; Henry AM; Lardas M; Liew M; Rouvière O; Pecanka J; Mason MD; Schoots IG; van Der Kwast TH; van Der Poel HG; Wiegel T; Willemse PM; Yuan Y; Lam TB; Cornford P; Mottet N
    Eur Urol; 2019 Jun; 75(6):967-987. PubMed ID: 30342843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
    Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
    Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
    Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
    Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
    Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
    J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer.
    Song C; Park S; Park J; Shim M; Kim A; Jeong IG; Hong JH; Kim CS; Ahn H
    Prostate; 2015 Feb; 75(2):211-7. PubMed ID: 25327522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Abdollah F; Suardi N; Capitanio U; Colombo R; Freschi M; Rigatti P; Montorsi F
    Cancer; 2011 Sep; 117(17):3953-62. PubMed ID: 21365624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
    Assel MJ; Ulmert HD; Karnes RJ; Boorjian SA; Hillman DW; Vickers AJ; Klee GG; Lilja H
    Prostate; 2020 Jan; 80(1):51-56. PubMed ID: 31603253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression.
    Schiffmann J; Salomon G; Tilki D; Budäus L; Karakiewicz PI; Leyh-Bannurah SR; Pompe RS; Haese A; Heinzer H; Huland H; Graefen M; Tennstedt P
    Urol Oncol; 2017 May; 35(5):243-249. PubMed ID: 28161322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL.
    Dariane C; Le Cossec C; Drouin SJ; Wolff B; Granger B; Mozer P; Bitker MO; Shariat SF; Cussenot O; Rouprêt M
    World J Urol; 2014 Apr; 32(2):481-7. PubMed ID: 23619479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of biochemical recurrence based on extent and location of positive surgical margins after robot-assisted laparoscopic radical prostatectomy.
    Marcq G; Michelet A; Hannink G; Rizk J; Sauvain J; Villers A; Saffarini M; Rochat CH
    BMC Cancer; 2018 Dec; 18(1):1291. PubMed ID: 30587172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
    Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
    Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.